BioPharma Credit (LSE:BPCR) Beginning Cash Position: $4.3 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LSE:BPCR BioPharma Credit PLC LSE:BPCR
52 GF Score
Price $0.96
GF Value $0.96
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is BioPharma Credit Beginning Cash Position?

BioPharma Credit LSE:BPCR +0.42% 52 Beginning Cash Position is $4.3 Mil as of Dec. 2025. GuruFocus rates LSE:BPCR with a GF Score™ of 52/100 and a GF Value™ of $0.96 (Fairly Valued). The stock has 2 warning signs investors should review.

BioPharma Credit's Beginning Cash Position for the quarter that ended in Dec. 2025 was $4.3 Mil.

BioPharma Credit's quarterly Beginning Cash Position declined from Dec. 2024 ($37.1 Mil) to Jun. 2025 ($5.6 Mil) and declined from Jun. 2025 ($5.6 Mil) to Dec. 2025 ($4.3 Mil).

BioPharma Credit's annual Beginning Cash Position increased from Dec. 2023 ($120.5 Mil) to Dec. 2024 ($135.1 Mil) but then declined from Dec. 2024 ($135.1 Mil) to Dec. 2025 ($5.6 Mil).

BioPharma Credit Beginning Cash Position Related Terms

BioPharma Credit Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for BioPharma Credit's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioPharma Credit Beginning Cash Position Chart

BioPharma Credit Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only 193.27 94.71 120.53 135.05 5.62

BioPharma Credit Semi-Annual Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 67.87 135.05 37.14 5.62 4.31
LSE:BPCR
52GF Score
BioPharma Credit PLC LSE:BPCR
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioPharma Credit Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $4.3 Mil mean?
BioPharma Credit (LSE:BPCR) has a Beginning Cash Position of $4.3 Mil as of Dec. 2025. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on BioPharma Credit and its competitors.
Is BioPharma Credit's Beginning Cash Position too high?
BioPharma Credit's current Beginning Cash Position is $4.3 Mil. Overall, BioPharma Credit has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioPharma Credit's Beginning Cash Position compare to BLK and BX?
BioPharma Credit's Beginning Cash Position of $4.3 Mil can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for an Asset Management company?
A good Beginning Cash Position depends on the Asset Management industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on BioPharma Credit and its competitors. BioPharma Credit's current Beginning Cash Position is $4.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioPharma Credit stock overvalued right now?
Based on GuruFocus' analysis, BioPharma Credit (LSE:BPCR) is currently considered Fairly Valued. The stock's GF Value™ is $0.96, compared to a current price of $0.96 — trading 0.4% above its estimated fair value. The current Beginning Cash Position is $4.3 Mil. BioPharma Credit's overall GF Score™ is 52/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For BioPharma Credit (LSE:BPCR), the current Beginning Cash Position is $4.3 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioPharma Credit (LSE:BPCR) Overvalued in 2026?

Based on GuruFocus' analysis, BioPharma Credit stock appears to be overvalued. The current stock price of $0.96 is trading 0.4% above its estimated GF Value™ of $0.96. GuruFocus considers BioPharma Credit to be Fairly Valued.

Key valuation signals for LSE:BPCR:

  • Beginning Cash Position: $4.3 Mil
  • GF Value™: $0.96 vs. price of $0.96 (0.4% above fair value)
  • GF Score™: 52/100 with 2 warning signs

No single metric tells the full story. See the LSE:BPCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioPharma Credit Business Description

Address c/o MUFG Corporate Governance Limited, 51 Lime Street, 19th Floor, London, GBR, EC3M 7DQ
BioPharma Credit PLC is an investment trust. Its investment objective is to generate long-term shareholder returns predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The trust focuses on achieving its investment objective through direct or indirect exposure to debt assets, which include royalty investments, senior secured debt, unsecured debt, and credit linked notes. Its diversified investment portfolio is mainly secured by approved life sciences products and the cash flows derived from their sales.
52GF Score

Get the complete analysis for LSE:BPCR

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.96
Price
$0.96
GF Value